title: Central toxic keratopathy after laser in situ keratomileusis.
abstract: OBJECTIVE
  To review cases of central toxic keratopathy (CTK) occurring over a period of 46 days.
  
  
  METHODS
  Moorfields Eye Hospital, London, United Kingdom.
  
  
  METHODS
  Retrospective consecutive case series.
  
  
  METHODS
  This was a review of patients with CTK after uneventful laser in situ keratomileusis (LASIK) performed by 1 of 5 surgeons at a single institute. The following parameters were analyzed: corrected distance visual acuity (CDVA), manifest refraction, and central corneal thickness from Scheimpflug pachymetry readings (Pentacam).
  
  
  RESULTS
  The cohort consisted of 15 eyes of 9 patients. Thirteen eyes were diagnosed within 7 days after LASIK, while the remaining 2 eyes developed CTK 12 days postoperatively. In 10 eyes, the time to resolution was 1 to 8 months. Five eyes still had residual signs at the last outpatient visit. At the final follow-up, 3 eyes (20%) had a CDVA worse than 0.0 logMAR.
  
  
  CONCLUSIONS
  Although a rare entity, CTK can occur in clusters. Although a cause was not fully isolated, ultimately each eye achieved excellent CDVA (all better than 0.2 logMAR) at the last follow-up.
authors.affiliation: From the Cornea and Refractive Surgery Service (Jutley, Aiello, Robaei, Maurino), Moorfields Eye Hospital, NHS Trust, London, United Kingdom, and the Department of Experimental Medicine (Aiello), Ophthalmology Unit, University of Rome Tor Vergata, Rome, Italy.
authors.forename: Gurjeet
authors.initials: G
authors.lastname: Jutley
authors.affiliation: From the Cornea and Refractive Surgery Service (Jutley, Aiello, Robaei, Maurino), Moorfields Eye Hospital, NHS Trust, London, United Kingdom, and the Department of Experimental Medicine (Aiello), Ophthalmology Unit, University of Rome Tor Vergata, Rome, Italy.
authors.forename: Francesco
authors.initials: F
authors.lastname: Aiello
authors.affiliation: From the Cornea and Refractive Surgery Service (Jutley, Aiello, Robaei, Maurino), Moorfields Eye Hospital, NHS Trust, London, United Kingdom, and the Department of Experimental Medicine (Aiello), Ophthalmology Unit, University of Rome Tor Vergata, Rome, Italy.
authors.forename: Dana
authors.initials: D
authors.lastname: Robaei
authors.affiliation: From the Cornea and Refractive Surgery Service (Jutley, Aiello, Robaei, Maurino), Moorfields Eye Hospital, NHS Trust, London, United Kingdom, and the Department of Experimental Medicine (Aiello), Ophthalmology Unit, University of Rome Tor Vergata, Rome, Italy. Electronic address: vincenzo.maurino@moorfields.nhs.uk.
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Maurino
mesh_terms: D000328:Adult; D000730:Androstadienes / Q000627:therapeutic use; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D003319:Corneal Stroma / Q000473:pathology*; D019781:Corneal Topography; D006801:Humans; D006956:Hyperopia / Q000601:surgery; D007634:Keratitis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D020731:Keratomileusis, Laser In Situ / Q000379:methods*; D054018:Lasers, Excimer / Q000627:therapeutic use*; D000069559:Loteprednol Etabonate; D008297:Male; D018613:Microscopy, Confocal; D009216:Myopia / Q000601:surgery; D011183:Postoperative Complications; D012029:Refraction, Ocular / Q000502:physiology; D012189:Retrospective Studies; D013524:Surgical Flaps / Q000473:pathology*; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000730:Androstadienes; D018926:Anti-Allergic Agents; D000069559:Loteprednol Etabonate